# US 2009/0270318 A1 · High-affinity antagonists of elr-cxc chemokines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270318 A1
- Document ID: US20090270318A1
- Status: Published application
- Kind: A1
- Application number: 12/301,102
- Filed: 2007-05-16
- Published: 2009-10-29
- Earliest claimed: 2006-05-16
- Assignees: University of Saskatchewan
- Inventors: John R. Gordon
- Web page: https://patentgrep.com/patent/US20090270318A1

## CPC

- C07K 14/522: {Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 31/04: Antibacterial agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/5421: {IL-8}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides novel polypeptide sequences, methods for production thereof and uses thereof for novel ELR-CXC chemokine receptor agonists and antagonists.

## Claims

### Claim 1

An isolated or purified peptide comprising an amino acid sequence of:
X1ELRCXCIRX XSXPFXPKXI XEXXXIXSPP HCXNXEIIVK
LXXGXEXCLX PXXXWVQXXV XXFXKXXEXX2X3X4
wherein X1, X2, X3 and X4 are independently 0-10 amino acid residues and X is any amino acid.

### Claim 2 (depends on 1)

The peptide according to claim 1 wherein X1 is 0-8 amino acids.

### Claim 3 (depends on 1)

The peptide according to claim 1 wherein each X1 is 0-6 amino acids.

### Claim 4 (depends on 1)

The peptide according to claim 1 wherein X1 is selected from the group consisting of GSK, GST, S, A, T, K, GSMGGSK, and GSMGGST.

### Claim 5 (depends on 1)

The peptide according to claim 1 wherein X1 is 0 amino acids.

### Claim 6 (depends on 1)

The peptide according to claim 1 with the proviso that the amino acid sequence is not as set forth in any one of SEQ ID No. 6-9.

### Claim 7 (depends on 1)

The peptide according to claim 1 comprising an amino acid sequence as set forth in SEQ ID No. 13.

### Claim 8

An isolated or purified peptide comprising an amino acid sequence of:
(SEQ ID No. 43)
X1ELRCX6CIRX10X11SX13PFX16PKX19I X21EX23X24X25IX27
SPPHCX33NX35EIIVK LX42X43GX45EX47CLX50 PX52X53X54W
VQX58X59VX61X62FX64KX66X67EX69X70X71X72
wherein:
X1, X70, X71 and X72 are independently 0-10 amino acids; and
X6, X10, X11, X13, X16, X19, X21, X23, X24, X25, X27, X33, X35, X42, X43, X45, X47, X50, X52, X53, X54, X58, X59, X61, X62, X64, X66, X67 and X69 are each independently selected from the group consisting of: A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V and Y.

### Claim 9 (depends on 8)

The peptide according to claim 8 wherein X1 is 0-8 amino acids.

### Claim 10 (depends on 8)

The peptide according to claim 8 wherein each X1 is 0-6 amino acids.

### Claim 11 (depends on 8)

The peptide according to claim 8 wherein X1 is selected from the group consisting of GSK, GST, S, A, T, K, GSMGGSK, and GSMGGST.

### Claim 12 (depends on 8)

The peptide according to claim 8 wherein X1 is 0 amino acids.

### Claim 13 (depends on 8)

The peptide according to claim 8 with the proviso that the amino acid sequence is not as set forth in any one of SEQ ID No. 6-9.

### Claim 14 (depends on 8)

The peptide according to claim 8 comprising an amino acid sequence as set forth in SEQ ID No. 13.

### Claim 15

An isolated or purified peptide comprising an amino acid sequence of:
(SEQ ID No. 4)
X1ELRCX6CIRX10X11SX13PFX16PKX19I X21EX23X24X25IX27
SPPHCX33NX35EIIVK LX42X43GX45EX47CLX50 PX52X53X54W
VQX58X59VX61X62FX64KX66X67EX69X70X71X72
wherein
X1 is 0-10 amino acids;
X6 is Q, E or L;
X10 is T or I;
X11 is H or Y;
X13 is T or K;
X16 is H or N;
X19 is F or Y or L;
X21 is K or R;
X23 is L or M;
X24 is R or T;
X25 is V or A;
X27 is D or E;
X33 is V or A or E;
X35 is T or S;
X42 is S or V or T or F;
X43 is D or N;
X45 is R or A or N or K or D;
X47 is L or V;
X50 is D or N;
X52 is K or H;
X53 is E or Q or T;
X54 is P or N or K;
X58 is R or K or I;
X59 is V or I;
X61 is E or Q;
X62 is K or I or V or A;
X64 is L or V;
X66 is R or K;
X67 is A or T;
X69 is S or N or K or G;
X70 is Q or S or K or deleted;
X71 is N or D or deleted; and
X72 is P or A or S or deleted.

### Claim 16 (depends on 15)

The peptide according to claim 15 wherein X1 is 0-8 amino acids.

### Claim 17 (depends on 15)

The peptide according to claim 15 wherein X1 is 0-6 amino acids.

### Claim 18 (depends on 15)

The peptide according to claim 15 wherein X1 is selected from the group consisting of: S, A, T, K, GSK, GST, GSMGGSK, GSMGGST or deleted.

### Claim 19 (depends on 15)

The peptide according to claim 15 with the proviso that the amino acid sequence is not as set forth in any one of SEQ ID No. 6-9.

### Claim 20

An isolated peptide consisting essentially of an amino acid sequence as set forth in any one of SEQ ID No. 10-41.

### Claim 21

An isolated polynucleotide sequence comprising a nucleotide sequence encoding an amino acid sequence of:
X1ELRCXCIRX XSXPFXPKXI XEXXXIXSPP HCXNXEIIVK
LXXGXEXCLX PXXXWVQXXV XXFXKXXEXX2X3X4
wherein X1, X2, X3 and X4 are independently 0-10 amino acid residues and X is any amino acid.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 21)

A transgenic cell comprising the polynucleotide according claim 21.

### Claim 41 (depends on 21)

A viral host genetically engineered to comprise the polynucleotide according to claim 21.

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48 (depends on 1)

A method of treating a CXC chemokine-mediated pathology comprising administering to an individual in need of such treatment an effective amount of a peptide according to claim 1.

### Claim 49 (depends on 48)

The method according to claim 48 wherein the CXC chemokine-mediated pathology is an ELR-CXC chemokine-mediated pathology.

### Claim 50 (depends on 49)

The method according to claim 49 wherein the CXC chemokine-mediated pathology is selected from the group consisting of: ischemia-reperfusion injury, endotoxemia-induced acute respiratory distress syndrome, immune complex-type glomerulonephritis, bacterial pneumonia and mastitis.
